Nobel Prize goes to technology for mRNA vaccines

Nobel Prize goes to technology for mRNA vaccines

Katalin Karikó, pictured, and Drew Weissman won the Nobel Prize for advances in mRNA research that led to the first Covid vaccines.

Adobe Stock

When Drew Weissman received a call from Katalin Karikó in the early morning hours this past Monday, he assumed his longtime research partner was calling to share a nascent, nagging idea. Weissman, a professor of medicine at the Perelman School of Medicine at the University of Pennsylvania, and Karikó, a professor at Szeged University and an adjunct professor at UPenn, both struggle with sleep disturbances. Thus, middle-of-the-night discourses between the two, often over email, has been a staple of their friendship. But this time, Karikó had something more pressing and exciting to share: They had won the 2023 Nobel Prize in Physiology or Medicine.


The work for which they garnered the illustrious award and its accompanying $1,000,000 cash windfall was completed about two decades ago, wrought through long hours in the lab over many arduous years. But humanity collectively benefited from its life-saving outcome three years ago, when both Moderna and Pfizer/BioNTech’s mRNA vaccines against COVID were found to be safe and highly effective at preventing severe disease. Billions of doses have since been given out to protect humans from the upstart viral scourge.

“I thought of going somewhere else, or doing something else,” said Katalin Karikó. “I also thought maybe I’m not good enough, not smart enough. I tried to imagine: Everything is here, and I just have to do better experiments.”

Unlocking the power of mRNA

Weissman and Karikó unlocked mRNA vaccines for the world back in the early 2000s when they made a key breakthrough. Messenger RNA molecules are essentially instructions for cells’ ribosomes to make specific proteins, so in the 1980s and 1990s, researchers started wondering if sneaking mRNA into the body could trigger cells to manufacture antibodies, enzymes, or growth agents for protecting against infection, treating disease, or repairing tissues. But there was a big problem: injecting this synthetic mRNA triggered a dangerous, inflammatory immune response resulting in the mRNA’s destruction.

While most other researchers chose not to tackle this perplexing problem to instead pursue more lucrative and publishable exploits, Karikó stuck with it. The choice sent her academic career into depressing doldrums. Nobody would fund her work, publications dried up, and after six years as an assistant professor at the University of Pennsylvania, Karikó got demoted. She was going backward.

“I thought of going somewhere else, or doing something else,” Karikó told Stat in 2020. “I also thought maybe I’m not good enough, not smart enough. I tried to imagine: Everything is here, and I just have to do better experiments.”

A tale of tenacity

Collaborating with Drew Weissman, a new professor at the University of Pennsylvania, in the late 1990s helped provide Karikó with the tenacity to continue. Weissman nurtured a goal of developing a vaccine against HIV-1, and saw mRNA as a potential way to do it.

“For the 20 years that we’ve worked together before anybody knew what RNA is, or cared, it was the two of us literally side by side at a bench working together,” Weissman said in an interview with Adam Smith of the Nobel Foundation.

In 2005, the duo made their 2023 Nobel Prize-winning breakthrough, detailing it in a relatively small journal, Immunity. (Their paper was rejected by larger journals, including Science and Nature.) They figured out that chemically modifying the nucleoside bases that make up mRNA allowed the molecule to slip past the body’s immune defenses. Karikó and Weissman followed up that finding by creating mRNA that’s more efficiently translated within cells, greatly boosting protein production. In 2020, scientists at Moderna and BioNTech (where Karikó worked from 2013 to 2022) rushed to craft vaccines against COVID, putting their methods to life-saving use.

The future of vaccines

Buoyed by the resounding success of mRNA vaccines, scientists are now hurriedly researching ways to use mRNA medicine against other infectious diseases, cancer, and genetic disorders. The now ubiquitous efforts stand in stark contrast to Karikó and Weissman’s previously unheralded struggles years ago as they doggedly worked to realize a shared dream that so many others shied away from. Katalin Karikó and Drew Weissman were brave enough to walk a scientific path that very well could have ended in a dead end, and for that, they absolutely deserve their 2023 Nobel Prize.

This article originally appeared on Big Think, home of the brightest minds and biggest ideas of all time.

Sign up for Big Think’s newsletter

Ross Pomeroy
Steven Ross Pomeroy is the editor of RealClearScience. As a writer, Ross believes that his greatest assets are his insatiable curiosity and his ceaseless love for learning. Follow him on Twitter
“Young Blood” Transfusions Are Not Ready For Primetime – Yet

A young woman donates blood.

(© Aidman/Fotolia)


Keep Reading Keep Reading
James Peyer
James Peyer, Ph.D. was only sixteen when he decided he would dedicate his life to preventing the diseases of aging. In 2016 he founded Apollo Ventures (www.apollo.vc), an early-stage venture capital firm and incubator with a focus on biotech companies that are creating the next generation of medicines: therapeutics to prevent age-related disease and extend healthy lifespan. Before Apollo he was a consultant with McKinsey & Company's biotech and pharma practice, where he specialized in biotech entrepreneurship, drug launches for regenerative medicines, and R&D pipeline analysis. He founded his first company, Genotyp, at age 21 to overhaul hands-on science education in the US. The first biotech company to receive funding through Kickstarter, Genotyp's biotech equipment leasing model and instructor training earned it the approval of the White House and the NIH. James received a BA in biology with special honors from the University of Chicago, where he was a National Merit Scholar. He received his Ph.D. from the University of Texas Southwestern Medical Center in Dallas, where he was a National Science Foundation Fellow with a focus on the basic biology of stem cells and improving gene therapies. The author declares no conflict of financial interest with the article written above.
Who’s Responsible for Curbing the Teen Vaping Epidemic?

A teenage girl vaping in a park.

(© DubstepWar/Fotolia)


Keep Reading Keep Reading
Noah Davis
Noah Davis is a writer living in Brooklyn. Visit his website at http://www.noahedavis.com.